adverse_JJ reactions_NNS -LRB-_-LRB- 1,2,3,4_CD -RRB-_-RRB- ._.
Independent_JJ ,_, parallel_JJ efforts_NNS have_VBP proceeded_VBN at_IN the_DT UK_NNP Medicines_NNP Control_NNP Agency_NNP -LRB-_-LRB- MCA_NNP -RRB-_-RRB- where_WRB Dr._NNP Stephen_NNP Evans_NNP has_VBZ explored_VBN the_DT use_NN of_IN proportional_JJ reporting_NN ratios_NNS -LRB-_-LRB- PRR_NN 's_POS -RRB-_-RRB- =_JJ -_: =[_NN 5_CD -RRB-_-RRB- -_: =_JJ -_: and_CC at_IN the_DT Uppsala_NNP Monitoring_NN Centre_NNP where_WRB Edwards_NNP ,_, Lindquist_NNP ,_, Bate_NNP and_CC others_NNS have_VBP pursued_VBN the_DT use_NN of_IN techniques_NNS based_VBN on_IN Bayesian_JJ neural_JJ networks_NNS -LRB-_-LRB- 6_CD -RRB-_-RRB- ._.
GlaxoSmithKline_NN -LRB-_-LRB- ``_`` GSK_NNP ''_'' -RRB-_-RRB- and_CC Lincoln_NNP Technologie_NNP
